NCT00021736View on ClinicalTrials.gov

Phase II/III Study of Anti-VEGF in Neovascular AMD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

July 31, 2001

Study Completion Date

July 31, 2002

Conditions
Macular DegenerationChoroidal Neovascularization
Interventions
DRUG

EYE001 anti-VEGF aptamer

Trial Locations (1)

Unknown

Foundation for Fighting Blindness, Baltimore

Sponsors
All Listed Sponsors
lead

Eyetech Pharmaceuticals

INDUSTRY